Announced
Completed
Financials
Sources
Tags
United States
healthcare industry
Private Equity
Biotechnology
Friendly
Acquisition
Completed
biotechnology company
biotechnology products
Minority
Single Bidder
Private
Venture Capital
Domestic
Synopsis
Asset management firm Viking Global Investors led a $120m Series B financing round for Affinivax, a clinical-stage biotechnology company. The round saw participation also from private equity firms Bain Capital Life Sciences and Ziff Capital Partners. “We are very pleased to welcome such a strong syndicate of new investors to Affinivax and look forward to benefiting from their deep experience. Having built the company to over 70 employees and advanced MAPS into clinical testing in less than 5 years, we are very excited to look ahead to our next phase of growth, taking our lead pneumococcal vaccine through Phase 3 testing and bringing several additional novel MAPS vaccines and immunotherapies into clinical trials," Steven B. Brugger, Affinivax CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.